...
机译:n-(3- {4- [3-(三氟甲基)苯基]哌嗪-1-基}丙基)-1H-吲唑-3-甲酰胺(D2aak3)作为潜在的抗精神病药:体外,在硅和体内评估中 多目标配体
Med Univ Lublin Dept Synth &
Chem Technol Pharmaceut Subst Fac Pharm Comp Modeling Lab 4A;
Med Univ Lublin Dept Biopharm Fac Pharm 4A Chodzki St PL-20093 Lublin Poland;
Med Univ Lublin Dept Synth &
Chem Technol Pharmaceut Subst Fac Pharm Comp Modeling Lab 4A;
Univ Santiago de Compostela Dept Pharmacol Ctr Res Mol Med &
Chron Dis CIMUS Avda Barcelona E;
Med Univ Lublin Dept Synth &
Chem Technol Pharmaceut Subst Fac Pharm Comp Modeling Lab 4A;
Med Univ Lublin Dept Pharmacol &
Pharmacodynam Fac Pharm 4A Chodzki St PL-20093 Lublin Poland;
Med Univ Lublin Dept Synth &
Chem Technol Pharmaceut Subst Fac Pharm Comp Modeling Lab 4A;
Med Univ Lublin Dept Pharmacol &
Pharmacodynam Fac Pharm 4A Chodzki St PL-20093 Lublin Poland;
Med Univ Lublin Dept Pharmacol &
Pharmacodynam Fac Pharm 4A Chodzki St PL-20093 Lublin Poland;
Univ Santiago de Compostela Dept Pharmacol Ctr Res Mol Med &
Chron Dis CIMUS Avda Barcelona E;
Antipsychotics; Central nervous system diseases; Dopamine receptors; G protein coupled receptors; Schizophrenia; Serotonin receptors;
机译:在某些体外和离体试验中,镇痛活性3- [4-(3-三氟甲基-苯基)-哌嗪-1-基]-二氢呋喃-2-酮对抗氧化剂状态,葡萄糖利用和脂质蓄积的影响
机译:可能多巴胺D-4受体的无载体添加的2-(3-(4-(4- [F-18]氟苄基)哌嗪-1-基)丙基)苯并[d]噻唑的合成及体外评价放射性配体
机译:新型N- [3-(4- {3-[(7-氯喹啉-4-基)氨基]丙基}哌嗪-1-基)丙基]羧酰胺的合成及抗血浆活性
机译:基于3-(4-(3-(双(4-(4-氟苯基)氨基)丙基)哌嗪-1-基)-3-苯基丙烷-1-醇的DAT /σ1双受体配体
机译:基于3-(4-(3-(Bis(4-氟苯基)氨基)丙基)哌嗪-1-基的受体配体 - 1-苯基丙烷-1-OL的双DAT /σ1受体配体
机译:Epa农药事实表:(Cas)N-(氰基甲基)-4-(三氟甲基)-3-(吡啶羧酰亚胺)或(UpaC)N-氰基甲基-4-三氟甲基烟酰胺(Flonicamid)